Skip to content
Cisatracurium besylate
Nimbex (cisatracurium besylate) is a small molecule pharmaceutical. Cisatracurium besylate was first approved as Nimbex on 1995-12-15.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Nimbex (generic drugs available since 2012-02-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cisatracurium besylate
Tradename
Company
Number
Date
Products
NIMBEXAbbVieN-020551 RX1995-12-15
1 products, RLD, RS
NIMBEX PRESERVATIVE FREEAbbVieN-020551 RX1995-12-15
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
cisatracurium besylateANDA2023-02-26
nimbexNew Drug Application2022-10-06
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
46 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuromuscular blockadeD019148—1—449
Respiratory distress syndromeD012128EFO_1000637J80——13—4
General anesthesiaD000768———134
AnesthesiaD000758———123
Delayed emergence from anesthesiaD055191———213
Postoperative complicationsD011183———112
Critical illnessD016638——11—2
Emergence deliriumD000071257———112
Patient-controlled analgesiaD016058———1—1
ArthroplastyD001178———1—1
Show 9 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FasciculationD005207R25.3——2——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437HP_0000083N19—1———1
Intraocular pressureD007429—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative painD010149G89.18————11
Muscle relaxationD009126————11
Urologic diseasesD014570N39.9————11
Gender identityD005783————11
Post-cardiac arrest syndromeD000080942————11
Brain neoplasmsD001932EFO_0003833C71————11
Intracranial aneurysmD002532EFO_0003870I67.1————11
Intratracheal intubationD007442————11
Intra-abdominal hypertensionD059325————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCISATRACURIUM BESYLATE
INNcisatracurium besilate
Description
Cisatracurium besylate is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium besylate. Commercial preparations of atracurium are mixtures of 10 stereoisomers, of which cisatracurium generally constitutes about 15%. Cisatracurium besylate is about 3 times more potent than the mixture of atracurium isomers as a neuromuscular blocking agent, and is used as a muscle relaxant for endotracheal intubation, to aid controlled ventilation, and in general anaesthesia. It has a role as a muscle relaxant and a nicotinic antagonist. It is a quaternary ammonium salt, an atracurium besylate and an organosulfonate salt. It contains a cisatracurium.
Classification
Small molecule
Drug classquaternary ammonium derivatives: neuromuscular blocking agents
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1
Identifiers
PDB—
CAS-ID96946-42-8
RxCUI136561
ChEMBL IDCHEMBL1200641
ChEBI ID3721
PubChem CID62886
DrugBankDB00565
UNII ID80YS8O1MBS (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 441 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cisatracurium besylate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
985 adverse events reported
View more details